COVID-19 Notice - We remain here for you and can answer any questions or concerns you may have. Learn More »
Justia Lawyer Rating
Badge - Massachusetts Bar Association
Badge - 2014 Top 40 Lawyer Under 40 ASLA
Badge - American Bar Association, Defending Liberty Pursuing Justice
Badge - American Association for Justice
Badge - Avvo Rating 10, Michael O Smith, Top Attorney
Badge - BBB Accredited Business
Badge - 10 Best Client Satisfaction, American Institute of Legal Counsel
Badge - Massachusetts Academy of Trial Attorneys
Badge - Rated by Super Lawyers 2019

Elmiron Lawsuits

Elmiron Maculopathy Case Representation in Massachusetts

People rely on prescription medications to be safe. When medications like Elmiron are not safe, the people who are injured may be entitled to compensation. Boston product liability attorney Michael O. Smith and his team of attorneys at Mass Injury Group can provide legal guidance and advice to the victims of medications like Elmiron.


ElmironElmiron, the brand name of pentosan polysulfate sodium (“PPS”), is a medication prescribed to treat symptoms of interstitial cystitis. Interstitial cystitis causes pressure and pain in the bladder. It is a chronic condition without a cure. The FDA approved Elmiron in 1996 and there is currently no generic equivalent. As the only oral drug approved by the FDA to treat the bladder discomfort and pain associated with interstitial cystitis, Elmiron has been widely used in interstitial cystitis patients, often long term and in large doses. While Elmiron may have provided relief to many people, serious concerns have arisen about the drug’s safety in recent years.

Elmiron and Maculopathy

In 2018, three doctors published a paper linking pigmentary maculopathy to chronic exposure to PPS. Additional studies have supported this finding. Maculopathy is a condition or disease of the part of the retina known as the macula. Pigmentary maculopathy involves changes in the retinal pigment epithelium. Patients report blurry vision, difficulty reading, and taking longer to adjust to low levels of light.

Janssen Pharmaceuticals, Inc., the manufacturer of Elmiron, did not include a warning regarding maculopathy until very recently. In 2020, the FDA approved a new label which added a warning about retinal pigmentary changes. The warning states that most cases occur after 3 years or more of use, but some cases have occurred in a shorter timeframe. The warning recommends an ophthalmologic history be taken for all patients and a comprehensive baseline retinal exam be taken for patients who have pre-existing eye conditions before they start taking Elmiron. It also recommends periodic retinal exams during treatment. “Pigmentary changes in the retina” has been added as an adverse reaction. The drug label was revised again in March 2021.

Although Elmiron now includes a warning regarding maculopathy, it was on the market for more than 20 years without such a warning. Many, many people took this medication without knowing the potential risk for eye damage. The Medication Guide in the most recent version of Elrimon’s drug label states that the pigment changes in the retina may continue even after a person stops taking Elmiron. It is unknown how many people may now be suffering from eye damage or vision loss without knowing the cause or how many people could be affected in the future.


Drug manufacturers should ensure their products are properly tested, manufactured and distributed. Additionally, they should provide instructions on use and warnings of any potential side effects. Manufacturers of unsafe drugs should be held responsible for the damage they cause. If you have been diagnosed with maculopathy after taking Elmiron, you deserve to be compensated for your injuries. Vision damage can significantly affect a person’s life. The damages that can be recovered will depend on the facts of each case but may include: medical expenses, pain and suffering, lost wages, and lost earning potential.

Experienced Boston Legal Counsel

Anyone who has developed eye or vision problems following use of Elmiron should consider discussing pigmentary maculopathy with a health care professional. It is sometimes misdiagnosed as other eye conditions. If you have been diagnosed with maculopathy after taking Elmiron, you should speak with a skilled Boston Elmiron maculopathy lawyer about your case. Attorney Michael O. Smith and Mass Injury Group can inform you of your legal options and advise you on your case. We are dedicated to serving clients in Boston and nearby areas. Your case will be handled on a contingency-fee basis, and the initial consultation is free. Contact us online or call (617) 263-0060 to schedule your consultation.

Client Reviews
"Tyler Langlais, an attorney at Mass Injury Group, handled my personal injury case in a most professional manner, and I was very pleased with the settlement he obtained for me. My case was pursued efficiently and expediently. Tyler kept me informed of progress each step of the way. I would recommend him highly to anyone who suffers the misfortune of a personal injury." Ed N
"A 35 year old traffic warrant for popped up when I applied for a DL in a new state. For a flat fee these guys helped me resolve the issue in a timely fashion. Dan Gallant was my main contact and he was fantastic. Lots of clear communication and follow through." Eric Jennings
"Top notch lawyer. Responsive to emails. Worked hard to get the settlement in a Worker's Comp case that was fair and equitable. Helped me navigate how the games that they played. Would recommend that others seek Michael for assistance in your cases as well. A good lawyer on your side is a must. A+." Jason Arroyo
"Tyler Langlais esq., quickly litigated and settled my case. He was extremely professional, down to earth, and very smart. I would recommend Tyler and his team of law professionals to all family and friends of mine." Jim DeStefano
"Attorney Michael Smith was very accommodating. I hate traveling into the city dealing with traffic, so he met me locally. He negotiated a fair settlement and I'm satisfied with his counsel." Myrienne